This Week in Cardiology

Listener feedback on the nonobstructive HCM trials, AI-enhanced visits, timing of non-culprit PCI in STEMI, new tricuspid valve intervention, and EP at a crossroads are the topics John Mandrola, MD, discusses in this week’s podcast.This podcast is intended for healthcare professionals only.To read a partial transcript or to comment, visit:https://www.medscape.com/twicI Listener Feedback  Koelemen meta-analysis https://www.medrxiv.org/content/10.64898/2026.09.08.26362195v1.full.pdf  Improving SCD Risk Stratification in HCM https://pmc.ncbi.nlm.nih.gov/articles/PMC11026183/II More on Nonobstructive HCM  Communication on Post-Hoc Analysis of ODYSSEY (mavacamten)  Mavacamten in Nonobstructive HCM 10.1016/j.jacc.2025.12.092III Complete vs Staged PCI in STEMI With Multivessel Disease   Immediate vs Staged CR in Multivessel Disease and STEMI: Meta-Analysis https://doi.org/10.1016/j.jcin.2026.07.033  Timing of Nonculprit PCI for STEMI and Multivessel Disease: Editorial https://doi.org/10.1016/j.jcin.2026.08.009  COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775  FLOWER MI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2104650  FRAME AMI Trial https://doi.org/10.1093/eurheartj/ehac763  iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918  COCUA Trial https://doi.org/10.1016/j.ahj.2023.01.020  MULTISTARS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307823  OPTION STEMI Trial 10.1016/S0140-6736(25)01529-6 External Link  CULPRIT SHOCK Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1710261  BioVasc Trial Substudy https://eurointervention.pcronline.com/article/immediate-versus-staged-complete-revascularisation-in-patients-presenting-with-stemi-and-multivessel-disease  Main BioVasc Trial 10.1016/S0140-6736(23)00351-3 External Link  FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149IV A Call to Action for Electrophysiologists   Twenty Years at the Crossroads 10.1016/j.jacep.2026.09.023  EP at a Crossroads - Josephson 2007 https://doi.org/10.1016/j.hrthm.2006.12.045  EP at a Crossroads: A Revisit - Josephson 2016 https://doi.org/10.1016/j.hrthm.2016.07.024V FDA Approves Another Tricuspid Valve Repair System  Press release https://www.edwards.com/newsroom/news/2026-10-21-fda-approval-of-edwards-lifesciences--pascal-preci  TRIC I HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2606934  CLASP II TR Trial https://pubmed.ncbi.nlm.nih.gov/42855029/The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected]  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Some promising studies in amyloidosis, aficamten in nonobstructive HCM, costs of the microaxial flow pump in cardiogenic shock, and more on the VESALIUS trial of evolocumab are the topics John Mandrola, MD, discusses in this week’s podcast.This podcast is intended for healthcare professionals only.To read a partial transcript or to comment, visit:https://www.medscape.com/twicI Light Chain Amyloidosis – A Potentially Helpful DrugAnselamimab Does Not Reduce Light-Chain Amyloidosis Deathshttps://www.medscape.com/viewarticle/anselamimab-does-not-reduce-light-chain-amyloidosis-deaths-2026a1000z79II Aficamten in Nonobstructive HCM: The ACACIA trialIII Microaxial Flow Pump Cost Analysis of Danger ShockIV More on Evolocumab at ESC: Vesalius Trial SubstudiesThe Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harringtonQuestions or feedback, please contact [email protected]://www.medscape.com/viewarticle/1003092 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listener feedback on POET II, sham control trials in atrial fibrillation, ICDs in HCM, and agenda laundering are the topics John Mandrola, MD, discusses in this week's podcast.This podcast is intended for healthcare professionals only.To read a partial transcript or to comment, visit:https://www.medscape.com/twicI Listener FeedbackPOET II Response-Tailored or Standard-Duration ABX for Infectious EndocarditisPOET I Trial https://www.nejm.org/doi/10.1056/NEJMoa1808312POET II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607887II PVI-SHAM-AF trial Back in the NewsGAP-AF Trial https://www.ahajournals.org/doi/10.1161/circep.115.003337PVI-SHAM-AF Trial 10.1016/S0140-6736(26)01558-8 External LinkWhy Sham Studies Are a Sham in 2026 10.1016/j.hrthm.2026.09.056 External LinkThe Indispensable Role of Sham Controls in Evaluating Interventional Therapies 10.1016/j.hrthm.2026.10.001 External LinkIII ICDs in HCMI CDs for the Prevention of SCD in High-Risk Patients with HCM https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.078597ICDs in HCM: Editorial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079687IV Agenda LaunderingHow Commercial “Agenda Laundering” Shapes Critical Care https://www.bmj.com/content/395/bmj-2026-100963The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harringtonQuestions or feedback, please contact [email protected] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listener feedback on DANISH-CRT, the POET II trial, a mechanistic study in obesity and AF, the DANCODE trial of slowing CAC progression, and more on GLP-1 drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback DANISH-CRT Trial 10.1016/S0140-6736(26)01597-7 Identifying LV Posterior Wall Delay in RBBB Using Lead V8 https://doi.org/10.1016/j.jacep.2026.03.009 Using Lead V8 as a Tool to Improve Patient Selection in CRT https://doi.org/10.1093/europace/euaf194 II POET II Response-Tailored or Standard-Duration Antibiotics for Endocarditis POET I https://www.nejm.org/doi/10.1056/NEJMoa1808312 POET II https://www.nejm.org/doi/full/10.1056/NEJMoa2607887 III Obesity and AF – A Neat Study from the Team in Prague LA Remodeling and Functional Maladaptations in Obesity https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.126.014509 IV Reducing CAC: The DANCODE Trial DANCODE Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.082363 V Two Big RCTs of New GLP-1 Drugs TRIUMPH-1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2604169 SYNCHRONIZE-2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607219 The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listener feedback, pulmonary embolism intervention, simple vs complex in BiV pacing, exercise in AF, and TAVR for paradoxical low-flow, low-gradient aortic stenosis are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback LBBP ICD Lead LEADR LBBAP Trial https://pubmed.ncbi.nlm.nih.gov/41110529/ TRIC-I-HF trial TRIC-I-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2606934 Growth of Tricuspid Interventions in Germany https://www.jacc.org/doi/10.1016/j.jcin.2025.05.030 II Treatment of Acute Intermediate-High Risk PE – the PRAGUE-26 Trial PRAGUE-26 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2608012 III Targeting CS leads in CRT devices – DANISH-CRT Trial DANISH-CRT Trial 10.1016/S0140-6736(26)01597-7 IV Exercise for AF, Especially When There Is LA Disease Physical Activity and Risk of Incident AF in Atrial Cardiomyopathy https://www.jacc.org/doi/10.1016/j.jacadv.2026.102999 V Paradoxical Low-Flow, Low-Gradient AS – REBOOT-PARADOX REBOOT-PARADOX trial 10.1016/j.jacc.2026.08.017 ROTAS Trial https://heart.bmj.com/content/110/20/1223 The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.